Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients — Stella

Home/Non-small Cell Lung Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Non-small Cell Lung Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Taiwan

China Medical University Hospital, Taichung

Key details

Phase

Early testing / Safety & dosing

Sponsor

China Medical University Hospital

Collaborators

China Medical University, Taiwan

Enrollment target

~20 participants

Started

February 2024

Primary completion

August 2026

Age range

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

20 Years – 70 Years

Last updated January 2025